Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Suspended 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × abarelix × Clear all
NCT00841113 2009-02-11

Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

Speciality European Pharma Limited

Phase 3 Completed
177 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00100243 2006-09-19

Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

PRAECIS Pharmaceuticals Inc.

Phase 2 Completed
22 enrolled
Genitourinary

Prostatic Neoplasms

NCT00103623 2006-09-19

The Plenaxis® Experience Study

PRAECIS Pharmaceuticals Inc.

Phase 4 Suspended
2,000 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡